Assembly Biosciences is advancing a new class of oral therapeutics for the treatment of hepatitis B (HBV) infection and novel oral live biotherapeutics for disorders associated with the microbiome.
Copyright West LLC. Minimum 15 minutes delayed.
- Assembly Biosciences Announces the Closing of its Public Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
- Assembly Biosciences Announces Pricing of $125 Million Public Offering
- Assembly Biosciences Announces Proposed Public Offering of Common Stock